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Background: The survival of unresectable pancreatic cancer patients is extremely poor. The aim of this study was
to examine if tumor size could predict survival length in order to optimize patient care.
Methods: A retrospective observational study was performed on 185 consecutive patients with unresectable
pancreatic cancer (ICD10: C250-2 and C258) who were diagnosed from 2003 to May 2010. The patients' initial
radiographs at presentation of symptoms were reviewed by the same radiologist, and tumor extent was
determined.
Results: The largest tumor diameter of the primary tumor was measured in 132 patients, 22 by an ultrasound and
the other patients by a CT scan. In 53 patients, the tumor size could not be delimited and measured. Seventy-five
patients (41%) had liver metastases at presentation of symptoms. Median survival for the entire patient group was
only 119 days. The median diameter of the patient’s largest tumor was 4.35 cm, while the sample groups ranged
from 1.2 to 14 cm. Patients were divided into two groups: those with a largest tumor diameter of ≤ 4.3 cm
(66 patients) and those with a largest tumor diameter of > 4.3 cm (66 patients). Median survival for these groups
was 149 and 94 days (p = 0.019), respectively. Cox regression showed a hazard ratio for tumor size of 1.48 (95% CI
1.02, 2.07) (p = 0.038), adjusted for the gemcitabine treatment which had been given to 49 patients and the
presence of liver metastasis. In 88 patients, stricture length could be measured at ERCP. When comparing stricture
lengths of ≤ 2 cm and > 2 cm, no difference in survival time was noted within a Kaplan-Meier analysis.
Conclusion: The size of the maximum tumor diameter of the primary tumor during the initial X-ray examination of
patients with pancreatic cancer may predict survival time for those patients who had no surgical resection. Stricture
length at ERCP gave no information on survival.
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Ductal pancreatic adenocarcinoma is one of the most
highly fatal cancers and is the fourth or fifth leading
cause of cancer death in the Western world. Five-year
survival is less than 5%, and in advanced pancreatic can-
cer, five-year survival is zero [1,2]. The high mortality
rate is due to the high incidence of metastatic disease at
diagnosis. Thus the prognosis of patients with unresect-
able pancreatic carcinoma is extremely poor. The disease
is difficult to treat because clinical presentation is often
late, and most of the patients have an advanced tumor
that is not resectable. Obstructive jaundice is the most
common symptom requiring palliation and presents in
70% of patients, while duodenal or gastric outlet ob-
struction presents in 10-25% [3]. Each year nearly 900
new pancreatic tumors are diagnosed in Sweden. Less
than 15% of these patients were treated by curative sur-
gical resection of the tumor area. The majority of
patients with locally advanced or metastatic tumor were
thus given palliative treatment. Although new and better
diagnostic methods have been developed, it is difficult to
identify, evaluate and determine the size and spread of
pancreatic cancer. Identification of biomarkers that ac-
curately predict disease survival and recurrence or would
provide clues for an individual risk assessment would be
of great help but are not yet feasible today in the ordin-
ary clinical setting [4], and methods such as radiographic
investigations must be used to inform decisions regard-
ing treatment choices and to predict survival length.
Furthermore, it is not possible to determine an exact
tumor node metastasis (TNM) classification status from
an unresectable pancreatic neoplasm as it requires a
pathological specimen, which can only be obtained from
an operation.
The purpose of this study was to examine whether
tumor size or length of bile duct stricture at initial
radiographic imaging may predict survival length in
patients with inoperable pancreatic cancer.
Methods
The study included consecutive patients diagnosed with
ductal pancreatic cancer during the period January 2003
to May 2010 and recruited from a single medical centre.
On starting the study all patients were deceased. Only
patients with a diagnosis of locally advanced cancer in
the caput, corpus and cauda of the pancreas, C250–2, or
carcinoma growth outside the pancreas into adjacent
organs, C258, according to ICD10 (International Classi-
fication of Diseases) were enrolled. All patients with
jaundice received biliary plastic or metal stents. Patients
who had surgery with curative purposes (i.e. Whipple
procedure) were excluded in this survey. Initial X-rays
following admittance to the hospital were reviewed by
the same radiologist, and tumor size was measuredagain. Tumor size was determined in several ways. Some
22 patients underwent only ultrasonography, and speci-
fied size values from the statement were used in these
cases. Most patients (161) were examined with an ordin-
ary contrast enhanced multislice computed tomography
(CT, slice thickness 2 mm), while only two patients were
examined with magnetic resonance imaging (MRI). The
surveys were reviewed and three size measurements
were determined: width, length and depth of the tumor
size. In 53 cases (29%), the tumor was too diffuse to be
measurable. To simplify the calculations in this study,
the maximum tumor diameter measured was that of the
primary tumor. The median maximum tumor diameter
was 4.35, and therefore the patient group was divided
into two groups: 66 patients with ≤ 4.3 cm maximum
tumor diameter and 66 patients with > 4.3 cm maximum
tumor diameter. Stricture length affecting the bile duct
was reexamined after the initial ERCP-examination in 66
patients. X-ray images were calibrated based on the
diameter of the endoscope (11.7 mm). Twenty patients
received percutaneous transhepatic cholangiography
(PTC). These X-rays could not be calibrated afterwards,
but the reported dimensions were used. Two patients
underwent an initial magnetic resonance cholangiopan-
creatography (MRCP) and the reexamined stricture
length was used. Stricture lengths affecting the bile duct
were divided by frequency determination in two equal
groups: ≤ 2 cm (44 patients) and > 2 cm (44 patients)
since stricture length’s mean and median was 2 cm.
Ethics
The study was approved by the Regional Ethical Review
Board in Lund, Sweden (EPN Dnr 2012/92).
Statistical analysis
The statistical analysis was performed using Stata ver-
sion 12.1 (StataCorp LP, College Station, Texas, USA).
Continuous variables are expressed as mean values with
standard deviation (SD) and were compared by two sam-
ple Student’s t-tests. The comparison among groups for
categorical variables was performed with Pearson chi2
tests. Overall survival estimates were calculated by the
Kaplan-Meier method, and the difference between
groups was assessed by the log rank test. Survival curves
were truncated at 24 months since the number of
patients at risk after that time was considered to be very
small. Independent factors for overall survival were
assessed with a Cox proportional-hazards regression
analysis. P < 0.050 was considered statistically significant.
Results
A total of 185 patients were included in the study. The
median age was 73.7 years old with a range of 43–
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Figure 2 Distribution of bile duct stricture length in 88
patients.
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median age of 72.7 years old (54–91 years old) (p = 0.30
for sex and age groups). Liver metastases were found in
75 patients (41%) at the initial radiological investigation.
The largest tumor diameter was determined in 132
patients but could not be measured in the other 53
patients. Figure 1 shows the distribution of tumor size.
The mean tumor diameter was 4.8 (SD 2.3) cm and me-
dian tumor size 4.35 cm with an interquartile range
(IQR) of 2.5. Stricture of the bile duct due to cancer
growth could be determined in 88 patients and the dis-
tribution is displayed in Figure 2. Mean stricture length
was 2.1 cm (SD 1.1) and median stricture length was
2.0 cm (IQR 1.5). Most of the tumors were located in
the caput region of the pancreas, Table 1. Patients who
received gemcitabine were divided into two groups clas-
sified by if at least one cycle of gemcitabine were given
or not. A cycle of gemcitabine consisted of three doses
once a week for 3 weeks followed by a 1-week break
in treatment. For the entire patient group, the median
survival time was 119 days, and the survival of different
tumor size groups is displayed in Table 2. The relation-
ship between tumor size and survival is shown in Figure 3
where the survival curves are adjusted for gemcitabine
treatment and occurrence of liver metastasis, and a signifi-
cant difference was found to be consistent throughout the
entire patient group. (p= 0.038). Bile duct stricture could
be analyzed in 88 patients, and the median length was
2.0 cm. Survival time was not longer in patients with stric-
ture length of less than 2 cm compared to those with a lar-
ger stricture length, Figure 4. Stricture length had no
predictive value on survival rate analyses, according to the
Cox regression (p= 0.730). There was also no correlation
between stricture length and tumor size. A Cox regression
was performed on tumor size, gemcitabine treatment and
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Figure 1 Distribution of the primary tumor's greatest diameter
in 132 patients.measurable tumor received gemcitabine, the median cycle
number was 4 (range 1 to 16 cycles).Discussion
In the current study, the median survival time for all
185 patients with unresectable ductal pancreatic adeno-
carcinoma was only 119 days, which is about the same
survival length reported by others [5,6]. The study
showed that tumor size of the primary tumor as mea-
sured at the patient’s initial X-ray examination may pre-
dict survival length, especially if the presence of liver
metastasis and gemcitabine therapy was taken into con-
sideration and adjusted for in the Cox regression. Stric-
ture length measured at ERCP was not a factor that
could predict survival duration. Stricture length was
divided into two groups (less than or equal to and
greater than 2 cm) in 88 patients, and a survival analysis
using the log rank test showed no significant difference




Mean age (SD), year 73.7 (10.7)
Visible tumor 132
Not possible to measure 53
Liver metastasis (%) 75 (41)
Patients with visible tumor 132
Mean age (SD), year 72.6 (11.0)
Female/male 75/57
Liver metastasis (%) 60 (45)
Tumor diameter≤ 4.3 cm 66
Tumor diameter > 4.3 cm 66
Gemcitabine treatment (%) 49 (37)
Table 2 Median survival time in days according to tumor size and liver metastasis
Tumor size N All patients No liver metastasis Liver metastasis
All studied patients 185 119 179 83
Diameter≤ 4.3 cm 66 149 204 111
Diameter > 4.3 cm 66 94 157 58
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length is an irrelevant prognosis factor for pancreatic
cancer, and this has not been described previously. It is
likely that the tumor grows asymmetrically and stricture
length is a misleading indicator of the actual tumor size.
If liver metastasis exists, patients have a significantly
shorter survival compared with patients without primary
liver metastasis. The difference was about 3 months.
Even when the pancreatic tumor was less than 4.3 cm,
there was a significant difference in survival time regard-
ing liver metastasis or not. Tumor biology is certainly
important and may partially explain the difference found
between the groups. The findings are in accord with a
recent German study where the only independent prog-
nostic factor for shorter survival was distant metastasis
[7]. A multivariable approach was used to account for
the functional form of the relationship between continu-
ous prognostic variable factors and survival in advanced
pancreatic cancer [5]. The study investigated multiple
clinical, histological, biochemical and demographic vari-
ables in the form of both binary and continuous mea-
surements. The model confirmed five prognostic factors,
namely albumin, CA19-9, alkaline phosphatase, lactate
dehydrogenase and metastases; and also identified three
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Figure 3 Survival analysis with tumor size in two groups: ≤ 4.3 cm, >
with gemcitabine, N = 132 (p = 0.038).aspartate aminotransferase and blood urea nitrogen.
Reported hazard ratios were between 2.08 and 1.50.
Tumor size was not included in the report, however,
which our study identified as an important variable for
predicting survival. Only early or late tumor stages were
used, and no significant difference in survival time was
found [5]. Prognostic factors for survival have been
described for patients who have undergone a surgical re-
section to treat their pancreatic cancer. But in the group
of patients with advanced adenocarcinoma, detailed data
on prognosis regarding tumor size and stricture length is
lacking. Some studies have focused on the value of CT
criteria in predicting survival rates for patients with po-
tentially resectable pancreatic head carcinoma [8,9]. One
of these studies included a small number of unresectable
patients and showed a poor 4 month survival rate for
these patients, but the only significant factors were
whether the superior mesenteric artery was encased by
the neoplasm or not and whether the tumor size was
more than 3 cm [8]. The results from another study sug-
gested that baseline performance status activity and the
occurrence of distant metastasis were the only variables
that could be independently associated with predicting
survival in patients with unresectable pancreatic carcin-
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Figure 4 Survival analysis in patients with two groups of stricture length affecting the bile duct, N = 88 (p= 0.49).
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study. This indicates that our study included patients
with an advanced disease status and that survival was
better predicted by using tumor size at the initial X-ray
examination than relying on baseline performance status
activity. Imaging studies play a crucial role in the diag-
nosis and management of patients with ductal pancreatic
adenocarcinoma. Multislice CT is the most widely avail-
able and best-validated modality for imaging patients
with pancreatic neoplasm. The sensitivity of CT for diag-
nosis of pancreatic adenocarcinoma, ranging 50–97%, and
its positive predictive value for predicting unresectability,
ranging 80 - 100%, are high but decreases for pancreatic
lesions smaller than 1.5 to 2 cm [11]. In our study, how-
ever, 29% of patients with unresectable cancer had tumors
that could not be defined or measured. Newer CT
machines with better image quality should make it easier
to find small tumors. In the future, better CT or MRI
computer protocols may improve the detection of pancre-
atic tumors but at present, semiautomatic computer pro-
grams are expected to render a measurement difference
of > 10% between radiologists [12]. Tumor volume asTable 3 Multivariable Cox regression in 132 patients with
measurable tumor The model had a chi2 value of 55.5
with 3 degrees of freedom
Hazard ratio 95% Conf. Interval P
Tumor size:
≤ 4.3 cm, > 4.3 cm
1.45 1.02 2.07 0.038
Gemcitabine
(no, yes)
0.33 0.22 0.49 <0.001
Liver metastasis
(no, yes)
3.26 2.17 4.91 <0.001measured by different radiological methods and calculated
as a square or bullet may lead to overestimations of tumor
volume. It would be better to use programs that recognize
the tumor in the pancreas and automatically calculate the
volume. Parlak et al. assessed whether gross tumor volume
determined by fusion of contrast-enhanced computerized
tomography (CT) and 18 F-fluoro-deoxy-D-glucose posi-
tron emission tomography-CT (FDG-PET-CT) based
radiotherapy could predict overall survival in 30 patients
with advanced pancreatic neoplasm and found that a vol-
ume of 91 cm3 corresponding to a tumor diameter of
5,58 cm predicted well survival [13]. They found 16.3 vs.
9.5 months of survival difference. However survival rates
were determined during radiotherapy and concurrent con-
tinuously infused 5-FU followed by 4 to 6 courses of main-
tenance gemcitabine and it is unclear if they adjusted for
the treatment.
Endoscopic ultrasound (EUS) is considered superior to
CT and MRI, especially in detecting small tumors and
lymph node metastasis. EUS can also be combined with
fine needle aspiration (FNA) and has a sensitivity of 85–
95% and a specificity of 97–100% [14]. Newer modalities
in conjunction with EUS are contrast-enhanced EUS and
tridimensional EUS, but all are operator dependent. It is
reasonable to state that the tumor size has a significant
impact on survival duration. This study used ordinary
diagnostic tools but although clearly illustrates that sur-
vival rates are higher for patients with small tumors. Cox
regression confirmed this finding even when the data was
adjusted for gemcitabine doses and the presence of liver
metastasis. Consequently, determining the largest tumor
diameter at the patient’s initial X-ray examination and
presence of liver metastasis can identify patients with a
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vive longer in order to allow for optimal individualized
patient care.
Conclusion
Determining the maximum tumor diameter of the pri-
mary tumor at the initial X-ray examination, but not
length of stricture at ERCP can predict survival time for
patients with unresectable pancreatic cancer.
Competing interests
No competing interests exist.
Authors' contributions
All authors substantially contributed to the current manuscript as listed
below. HF drafted the manuscript, is the principal investigator of the study
and designed this study. KP reviewed and measured tumor size of all X-rays.
MW, KP, HK revised the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The study was supported by grants from Blekinge County Council’s Research
and Development Fund.
Author details
1Dept of Surgery, Blekinge Hospital, 371 85 Karlskrona, Sweden. 2Blekinge
Centre of Competence, Blekinge 371 81 Karlskrona, Sweden. 3Dept of
Radiology, Blekinge Hospital, 371 85 Karlskrona, Sweden. 4Blekinge Institute
of Technology, School of Health Science, 371 79 Karlskrona, Sweden.
Received: 5 June 2012 Accepted: 20 September 2012
Published: 25 September 2012
References
1. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence
and mortality in Europe in 2008. Eur J Cancer 2010, 46:765–781.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
3. Gentileschi P, Kini S, Gagner M: Palliative laparoscopic hepatico- and
gastrojejunostomy for advanced pancreatic cancer. JSLS 2002, 6:331–338.
4. Ansari D, Rosendahl A, Elebroand J, Andersson R: Systematic review of
immunohistochemical biomarkers to identify prognostic subgroups of
patients with pancreatic cancer. Br J Surg 2011, 98:1041–1055.
5. Stocken DD, Massan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ,
Freemantle N: Modelling prognostic factors in advanced pancreatic
cancer. Br J Cancer 2008, 99:883–893.
6. Engelken FJF, Bettschart V, Rahman MQ, Parks RW, Garden OJ: Prognostic
factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003,
29:368–373.
7. Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM, Prinz
C: Prognostic factors for survival in patients with unresectable pancreatic
cancer. Pancreas 2010, 39:247–253.
8. Phoa SS, Tilleman EH, van Delden OM, Bossuyt PM, Gouma DJ, Laméris JS:
Value of CT criteria in predicting survival in patients with potentially
resectable pancreatic head carcinoma. J Surg Oncol 2005, 91:33–40.
9. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E:
Prognostic factors in the operative and palliative treatment of pancreatic
cancer. Neoplasma 2003, 50:383–387.
10. Cubiella J, Castells A, Fondevila C, Sans M, Sabater L, Navarro S,
Fernandez-Cruz L: Prognostic Factors in Nonresectable Pancreatic
Adenocarcinoma: A Rationale to Design Therapeutic Trials. Am J
Gastroenterol 1999, 94:1271–1278.
11. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging
studies. Clin Gastroenterol Hepatol 2008, 6:1301–1308.
12. Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E: Comparison of
the Accuracy of CT Volume calculated by circumscription to prolate
ellipsoid volume (bidimensional measurement multiplied by coronal
long axis). Acad Radiol 2009, 16:181–186.13. Parlak C, Topkan E, Onal C, Reyhan M, Selek U: Prognostic value of gross
tumor volume delineated by FDG-PET-CT based radiotherapy treatment
planning in patients with locally advanced pancreatic cancer treated
with chemoradiotherapy. Radiat Oncol 2012, 7:37.
14. Krishna S, Lee HJ: Endosonography in solid and cystic pancreatic tumors.
J Interv Gastroenterol 2011, 1:193–201.
doi:10.1186/1471-2407-12-429
Cite this article as: Forssell et al.: Tumor size as measured at initial X-ray
examination, not length of bile duct stricture, predicts survival in
patients with unresectable pancreatic cancer. BMC Cancer 2012 12:429.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
